QUARTERLY REPORT OF PURE BIOLOGICS S.A. FOR THE Q3 2023
pursuant to § 60.1.1 of the Regulation on current and periodic information
for issuers of securities engaged in manufacturing, construction, trade or service activities
for Q3 of the financial year 2023 covering the period from 2023-07-01 to 2023-09-30
containing financial statements in accordance with IAS in PLN currency
report date: 2023-11-15
correction date: 2023-12-12
| SELECTED FINANCIAL DATA | thousand PLN | thousand PLN | thousand EUR | thousand EUR |
| 01.01.2023-30.09.2023 | 01.01.2022-30.09.2022 | 01.01.2023-30.09.2023 | 01.01.2022-30.09.2022 | |
| I. Operating income | 16 598 | 9 702 | 3 626 | 2 030 |
| II. Total operating expenses | 36 967 | 27 088 | 8 076 | 5 668 |
| III. Operating profit (loss) | (21 860) | (17 327) | (4 776) | (3 626) |
| IV. Profit (loss) before tax | (24 556) | (18 443) | (5 365) | (3 859) |
| V. Net profit (loss) | (24 556) | (18 443) | (5 365) | (3 859) |
| VI. Weighted average number of ordinary shares | 3 168 286 | 2 254 000 | 3 168 286 | 2 254 000 |
| VII. Profit (loss) per ordinary share (in PLN/EUR) | (7,75) | (8,18) | (1,69) | (1,71) |
| VIII. Net cash flow from operating activities | (19 779) | (12 290) | (4 321) | (2 572) |
| IX. Net cash flow from investing activities | 763 | 23 303 | 167 | 4 876 |
| X. Net cash flow from financing activities | 23 385 | (1 517) | 5 109 | (317) |
| XI. Total net cash flow | 4 369 | 9 496 | 955 | 1 987 |
| 30.09.2023 | 31.12.2022 | 30.09.2023 | 31.12.2022 | |
| XII. Total assets/liabilities | 65 177 | 33 009 | 14 060 | 7 038 |
| XIII. Tangible assets | 34 901 | 8 838 | 7 529 | 1 884 |
| XIV. Current assets | 30 276 | 24 171 | 6 531 | 5 154 |
| XV. Equity capital | 13 020 | 18 297 | 2 809 | 3 901 |
| XVI. Liabilities and provisions for liabilities | 52 158 | 14 712 | 11 252 | 3 137 |
| XVII. Long-term liabilities | 38 416 | 1 877 | 8 287 | 400 |
| XVIII. Short-term liabilites | 13 742 | 12 834 | 2 964 | 2 737 |
| XIX. Number of shares at the end of the period | 3 214 000 | 2 254 000 | 3 214 000 | 2 254 000 |
| XX. Book value per share (in PLN /EUR) | 4,05 | 8,12 | 0,87 | 1,73 |
|
The selected financial figures presented in the report have been converted into euro as follows: |
||||
| 1) Items relating to the statement of profit or loss and other total income, the cash flow statement and the statement of changes in equity were converted at an exchange rate representing the arithmetic average of the exchange rates published by the National Bank of Poland: | ||||
| – for period 01.01.2023 – 30.09.2023: PLN 4.5773 | ||||
| – for period 01.01.2022 – 30.09.2022: PLN 4.7787 | ||||
| 2) Items in the statement of financial position were translated at the average exchange rate announced by the National Bank of Poland (NBP), as at the balance sheet date; this rate was: | ||||
| – as on 30.09.2023: PLN 4.6356 | ||||
| – as on 31.12.2022: PLN 4.6899 | ||||
CORRECTION OF THE REPORT
The Management Board of Pure Biologics S.A. with its registered office in Wrocław (the “Company”), acting on the recommendation given to the Company by the Financial Supervision Authority, hereby provides a correction to the content of the interim report for Q3 2023 published by the Company on 15 November 2023 (the “Interim Report”) consisting of (i) an amendment to the information contained in the Company’s abbreviated financial statements for the period 01.07.2023 – 30.09.2023 (the “Financial Statements”) information on the risks and assumptions made in the assessment by the Company’s Management Board of the Company’s ability to continue as a going concern, based on an analysis of the Company’s current and projected financial and liquidity position, taking into account in particular cash flow projections for a 12-month period, and (ii) an update of the information provided in the Financial Statements on the going concern assumption made by the Company’s Management Board, including judgments and assumptions concerning the future, which changes and updates were made in Section. V.5 of the Financial Statements (Basis of preparation of the financial statements).
As part of this revision of the Interim Report, the Company has also revised the correction included in para. VII.7 (Explanatory Note No. 7 to the Statement of Financial Position) of an obvious clerical error concerning the Company’s shareholding structure.
The remaining financial information and data contained in the Interim Report remain unchanged.
The Company submits the corrected Interim Report as an attachment.
Detailed legal basis: § 15 (4) of the Regulation of the Minister of Finance of 29 March 2018 on current and periodic information provided by issuers of securities and conditions for recognising as equivalent information required by the laws of a non-member state
Filip Jeleń – President of the Board
Romuald Harwas – Vice President of the Board
Petrus Spee – Vice President of the Board